High ROIC Stocks
HALO is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
HALOZYME THERAPEUTICS INC (HALO) Stock Price & Overview
NASDAQ:HALO • US40637H1095
Current stock price
64.63 USD
+2.5 (+4.02%)
At close:
64.5 USD
-0.13 (-0.2%)
After Hours:
The current stock price of HALO is 64.63 USD. Today HALO is up by 4.02%. In the past month the price decreased by -6.87%. In the past year, price increased by 8.13%.
HALO Key Statistics
52-Week Range47.5 - 82.22
Current HALO stock price positioned within its 52-week range.
1-Month Range61.325 - 71.53
Current HALO stock price positioned within its 1-month range.
- Market Cap
- 7.628B
- P/E
- 15.65
- Fwd P/E
- 7.90
- EPS (TTM)
- 4.13
- Dividend Yield
- N/A
HALO Stock Performance
Today
+4.02%
1 Week
+4.17%
1 Month
-6.87%
3 Months
-8.08%
Longer-term
6 Months -6.31%
1 Year +8.13%
2 Years +58.87%
3 Years +69.23%
5 Years +55.03%
10 Years +582.47%
HALO Stock Chart
HALO Stock Screens
HALO currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
HALO is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
HALO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HALO. When comparing the yearly performance of all stocks, HALO is a bad performer in the overall market: 61.24% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
HALO Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to HALO. HALO gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
HALO Earnings
On February 17, 2026 HALO reported an EPS of -0.24 and a revenue of 451.77M. The company missed EPS expectations (-110.7% surprise) and beat revenue expectations (1.13% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 17, 2026
PeriodQ4 / 2025
EPS Reported-$0.24
Revenue Reported451.767M
EPS Surprise -110.70%
Revenue Surprise 1.13%
HALO Forecast & Estimates
15 analysts have analysed HALO and the average price target is 86.19 USD. This implies a price increase of 33.36% is expected in the next year compared to the current price of 64.63.
For the next year, analysts expect an EPS growth of 97.97% and a revenue growth 26.75% for HALO
Analysts
Analysts76
Price Target86.19 (33.36%)
EPS Next Y97.97%
Revenue Next Year26.75%
HALO Groups
Sector & Classification
HALO Financial Highlights
Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 4.13. The EPS decreased by -2.36% compared to the year before.
Income Statements
Revenue(TTM)1.40B
Net Income(TTM)316.89M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.69% | ||
| ROA | 12.55% | ||
| ROE | 649.18% | ||
| Debt/Equity | 43.89 |
Chartmill High Growth Momentum
EPS Q2Q%-119.05%
Sales Q2Q%51.6%
EPS 1Y (TTM)-2.36%
Revenue 1Y (TTM)37.55%
HALO Ownership
Ownership
Inst Owners107.69%
Shares118.02M
Float116.54M
Ins Owners0.87%
Short Float %11.76%
Short Ratio7.57
HALO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.66 | 384.559B | ||
| AMGN | AMGEN INC | 15.42 | 189.672B | ||
| GILD | GILEAD SCIENCES INC | 15.77 | 173.017B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.03 | 113.435B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.53 | 81.684B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.35 | 43.88B | ||
| INSM | INSMED INC | N/A | 35.247B | ||
| NTRA | NATERA INC | N/A | 28.345B | ||
| BIIB | BIOGEN INC | 11.4 | 26.906B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.85 | 25.99B | ||
| MRNA | MODERNA INC | N/A | 20.063B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.272B | ||
| INCY | INCYTE CORP | 12.29 | 18.731B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HALO
Company Profile
The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30.
Company Info
IPO: 2003-01-30
HALOZYME THERAPEUTICS INC
12390 El Camino Real
San Diego CALIFORNIA 92121-1345 US
CEO: Helen I. Torley
Employees: 423
Phone: 13026587581
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you describe the business of HALOZYME THERAPEUTICS INC?
The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30.
Can you provide the latest stock price for HALOZYME THERAPEUTICS INC?
The current stock price of HALO is 64.63 USD. The price increased by 4.02% in the last trading session.
Does HALO stock pay dividends?
HALO does not pay a dividend.
What is the ChartMill rating of HALOZYME THERAPEUTICS INC stock?
HALO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the PE ratio for HALO stock?
The PE ratio for HALOZYME THERAPEUTICS INC (HALO) is 15.65. This is based on the reported non-GAAP earnings per share of 4.13 and the current share price of 64.63 USD.
What is the market capitalization of HALO stock?
HALOZYME THERAPEUTICS INC (HALO) has a market capitalization of 7.63B USD. This makes HALO a Mid Cap stock.